Log in
Enquire now
‌

US Patent 9828427 Anti-KIR3D antibodies

Patent 9828427 was granted and assigned to Innate Pharma on November, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Innate Pharma
Innate Pharma
0
Current Assignee
Innate Pharma
Innate Pharma
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
98284270
Patent Inventor Names
Laurent Gauthier0
Yannis Morel0
Silvia Parolini0
Alessandro Moretta0
Benjamin Rossi0
Nicolas Anfossi0
Date of Patent
November 28, 2017
0
Patent Application Number
149247860
Date Filed
October 28, 2015
0
Patent Primary Examiner
‌
Nora Rooney
0
Patent abstract

The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9828427 Anti-KIR3D antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.